Browsing by Author "Henderson, Robert J"
Now showing 1 - 2 of 2
- Results Per Page
- Sort Options
Item Open Access Clinical Trial of Losartan for Pulmonary Emphysema: Pulmonary Trials Cooperative LEEP Trial.(American journal of respiratory and critical care medicine, 2022-06) Wise, Robert A; Holbrook, Janet T; Brown, Robert H; Criner, Gerard J; Dransfield, Mark T; He, Jiaxian; Henderson, Robert J; Kaminsky, David A; Kaner, Robert J; Lazarus, Stephen C; Make, Barry J; McCormack, Meredith C; Neptune, Enid R; Que, Loretta GRationale
There are no pharmacologic agents that modify emphysema progression in patients with chronic obstructive pulmonary disease (COPD).Objective
Evaluate the efficacy of losartan, an angiotensin receptor blocker (ARB), to reduce emphysema progression.Methods
The trial was a multicenter randomized placebo-controlled trial, conducted between May 2017 and January 2021. Eligible participants were age ≥40, had moderate to severe airflow obstruction, ≥10 pack-years smoking, mild-moderate emphysema on high-resolution computed tomography (HRCT), and no medical indication for or intolerance of ARBs. Treatment with losartan, 100 mg daily, or matching placebo (1:1) was randomly assigned. The primary outcome was emphysema progression on HRCT over 48 weeks. Secondary outcomes included St George's Respiratory Questionnaire (SGRQ), modified Medical Research Council dyspnea scale, COPD Assessment Test, Physical Function-Short Form 20a (PROMIS 20a).Results
220 participants were enrolled; 58% were men, 19% were African American; and 24% current smokers. The medians (interquartile ranges) for age were as 65 (61, 73) years, and 48 (36, 59) for percent predicted FEV1 post-bronchodilator. The mean (95% confidence interval) percent emphysema progression was 1.35% (0.67, 2.03) in the losartan group vs 0.66% (0.09, 1.23) in placebo (P = NS).Conclusions
Losartan did not prevent emphysema progression in people with COPD with mild-moderate emphysema. Clinical trial registration available at www.Clinicaltrials
gov, ID: NCT02696564.Item Unknown Refractive Error Change and Overminus Lens Therapy for Childhood Intermittent Exotropia(JAMA Ophthalmology) Alexander, Monsey L; Allen, Megan; Alluri, Sreevardhan; Amster, Deborah M; Anderson, Heather A; Argoubi, Afifa; Astle, William F; Austin, Darrell S; Bailey, Maragaret K; Baker, John D; Beaulieu, Wesley T; Beck, Roy W; Berns, Fabiana; Bhatt, Amit R; Birch, Eileen E; Bitner, Derek P; Bland, Tracy A; Bodack, Marie I; Boente, Charline S; Bohra, Lisa; Bond, Lezlie L; Bothun, Erick D; Boyle, Nicole M; Brafford, Randy C; Castle, Kelly M; Chamberlain, Carolyn; Cheung, Nathan L; Christiansen, Stephen P; Christoff, Alex; Chung, Ida; Cioffi, Katherine R; Clausius, Deborah A; Cobb, Patricia; Collins, Mary Louise Z; Colon, Beth J; Conley, Julie A; Conner, Courtney L; Connolly, Katie S; Cooper, Karen; Crossnoe, Connie J; Crouch, Eric R; Cupit, Shawn L; Curtis, Linda T; Cutrer, Beth M; Davis, Barry; de Alba Campomanes, Alejandra G; De Leon, Erika A; Dean, Trevano W; Diener-West, Marie I; Dillon, Angela C; Dinani, Zainab; Donahue, Quayleen; Donahue, Sean P; Droste, Patrick J; Ecerova, Zuzana; Eltzroth, Jillian M; Esposito, Christina A; Evans, Patricia L; Everett, Donald F; Fang, Caroline C; Feis, Alicia E; Fergus, Lisa M; Fimbel, Brooke P; Fishman, Deborah R; Flanagan, Maureen A; Forde, Roberta A; Fouzdar Jain, Samisksha; Franklin, John Mark; Frazier, Marcela; Gafford, Jennifer B; Geddie, Brooke E; Gertsch, Kevin R; Gianfermi, Elena; Gray, Michael E; Grigorian, Adriana P; Gunton, Kammi B; Hahn, Alexis C; Hahn-Parrott, Laurie; Haider, Kathryn M; Haley, Wendy Jean; Hatch, Stanley W; Hatt, Sarah R; Henderson, Robert J; Heyman, Catherine L; Higgins, Rosemary D; Hilbrands, Jan; Hoepner, James E; Holleschau, Ann M; Holtorf, Hannah L; Hoover, Darren L; Hopkins, Kristine B; Huang, Kristine; Hutchinson, Amy K; James, Yvonne R; Jastrzemsbki, Benjamin G; Jenewein, Erin C; Jensen, Allison A; Jhajj, Jasleen K; Jones, Sarah K; Jordan, Catherine O; Kaplon, Joseph D; Khan, Shabana; Klaehn, Lindsay D; Kong, Lingkun; Koontz, Emily R; Koutnik, Cassandra A; Kramer, Andrea M; Kraus, Courtney L; Krueger, Samantha L; Kulp, Marjean T; Kurup, Sudhi P; LaMattina, Kara C; Lambert, Jennifer E; Lambert, Scott R; Law, Cristina L; Lazar, Elizabeth L; Leach, Shelby; Lee, Katherine A; Leske, David A; Li, Zhuokai; Lim, Maria E; Liu, Xiaonong; Lorenzana, Ingryd; Loud, Rachel N; Lyon, Don W; Lyons, Alex F; Manuchian, Sonia; Marozas, Lauren; Marsh, Justin D; Martinson, Stacy R; May, Laura M; McCoy Vrablec, Laura; McMurtrey, J Ryan; Meil, Gail C; Melia, B Michele; Merrill, Kim S; Mets-Halgrimson, Rebecca B; Meyers, Sara R; Miller, Aaron M; Miller, Caiytlin C; Mohney, Brian G; Montejo, Jenifer; Morgan, Linda; Morrison, Kelsie B; Morrison, Ann M; Morrison, David G; Myung, Jenny; Nash, David L; Nylin, Elyse; Oechslin, Tamara S; Olvera, Maria N; Ortiz, Gillaine; Oseguera, Teresa; Pang, Yi; Parker, Sue M; Patel, Reena A; Paysse, Evelyn A; Peragallo, Jason H; Perzyk, Susan N; Peters, Robert J; Phillips, Paul H; Plaumann, Maureen D; Plum, Larry W; Poff, Stephen W; Pollack, Karen E; Qayum, Jennifer N; Quebbemann, Micaela N; Raghuram, Aparna; Rahmani, Bahram; Ralay Ranaivo, Hantamalala; Repka, Michael X; Retnasothie, Dashaini V; Roberts, Tawna L; Robinson, Julianne L; Roe, Matthew K; Romany, Gihan; Rutner, Daniella; Sala, Allyson; Sanders, Emi N; Saunders, Richard A; Sayani, Amar; Scheiman, Mitchell M; Schulman-Ellis, Erica L; Shah, Birva K; Shah, Veeral S; Shelton, Erica R; Siatkowski, R Michael; Slinger, Kristin E; Smith, Rachel M; Solis, Casandra S; Stec, Magdalena; Stevens, Nancy E; Stevens, Julia L; Stewart, Miqua L; Strul, Sasha; Stutz, Kathleen M; Suh, Donny W; Summers, Allison I; Superstein, Roseanne; Sutherland, Desirae R; Tamkins, Susanna M; Taub, Marc B; Thibeault, Maryse; Titelbaum, Jenna R; Tolbert, Tiffany T; Toole, Andrew J; Toro, David O; Tung, Irene T; Twardowski, Christina M; Tychsen, Lawrence; Tzanetakos, Vivian; Varney, Kelly D; Ventura, Gaylord G; Verderber, Lisa C; Walker, Kimberly R; Wall, Palak B; Wallace, David K; Wang, Jingyun; Weise, Katherine K; Wernimont, Suzanne M; Willen, Christi M; Wolinski, Elisabeth T; Woodard, Victoria C; Wright, Martha M; Yamada, Tomohiko; Yen, Kimberly G; Yonkers, Amanda M; Freedman, Sharon F; Christian, Melanie L; Crouch, Earl R; Enyedi, Laura B; Good, William V; Jackson, Jorie L; London, Richard; Manh, Vivian M; Manny, Ruth E; Morrell, Beth A; Petersen, David B; Pineles, Stacy L; Rogers, David L; Ruark, Scott T; Schweinler, Bonita R; Silver, Jayne L; Chen, Angela M; Erzurum, S Ayse; Chandler, Danielle L; Hercinovic, Amra; Wu, Rui; Vricella, Marilyn; Waters, Amy L; Ticho, Benjamin H; Erickson, John W; Han, Silvia; McDowell, Paula S; Li, Zhuokai; Kraker, Raymond T; Holmes, Jonathan M; Cotter, Susan AImportanceIncreased myopic shift was found to be associated with 1 year of overminus spectacle treatment for children with intermittent exotropia (IXT). Persistence of myopic shift after discontinuing overminus spectacles is unknown.ObjectiveTo compare refractive error change over 3 years in children with IXT originally treated with overminus vs nonoverminus spectacles.Design, Setting, and ParticipantsThis study was an 18-month extension of the Trial of Overminus Spectacle Therapy for Intermittent Exotropia cohort, which previously randomized children aged 3 to 10 years with IXT and baseline spherical equivalent refractive error (SER) between −6.00 diopters (D) and 1.00 D to overminus spectacles (−2.50 D for 12 months, −1.25 D for 3 months, and nonoverminus for 3 months) or nonoverminus spectacles. Children were recruited from 56 sites from July 2010 to February 2022. Data were analyzed from February 2022 to January 2024.InterventionsAfter trial completion at 18 months, participants were followed up at 24 and 36 months. Treatment was at investigator discretion from 18 to 36 months.Main Outcomes and MeasuresChange in SER (cycloplegic retinoscopy) from baseline to 36 months.ResultsOf 386 children in the Trial of Overminus Spectacle Therapy for Intermittent Exotropia, 223 (57.8%) consented to 18 months of additional follow-up, including 124 of 196 (63.3%) in the overminus treatment group and 99 of 190 (52.1%) in the nonoverminus treatment group. Of 205 children who completed 36-month follow-up, 116 (56.6%) were female, and the mean (SD) age at randomization was 6.2 (2.1) years. Mean (SD) SER change from baseline to 36 months was greater in the overminus group (−0.74 [1.00] D) compared with the nonoverminus group (−0.44 [0.85] D; adjusted difference, −0.36 D; 95% CI, −0.59 to −0.12; P = .003), with 30 of 112 (26.8%) in the overminus group having more than 1 D of myopic shift compared with 14 of 91 (15%) in the nonoverminus group (risk ratio, 1.8; 95% CI, 1.0-3.0). From 12 to 36 months, mean (SD) myopic shift was −0.34 (0.67) D and −0.36 (0.66) D in the overminus and nonoverminus groups, respectively (adjusted difference, −0.001 D; 95% CI, −0.18 to 0.18; P = .99).Conclusions and RelevanceThe greater myopic shift observed after 1 year of −2.50-D overminus lens treatment remained at 3 years. Both groups had similar myopic shift during the 2-year period after treatment weaning and cessation. The risk of myopic shift should be discussed with parents when considering overminus lens treatment.Trial RegistrationClinicalTrials.gov Identifier: NCT02807350